226 related articles for article (PubMed ID: 20015594)
1. SRC kinase inhibition: targeting bone metastases and tumor growth in prostate and breast cancer.
Saad F; Lipton A
Cancer Treat Rev; 2010 Apr; 36(2):177-84. PubMed ID: 20015594
[TBL] [Abstract][Full Text] [Related]
2. Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.
Edwards J
Expert Opin Investig Drugs; 2010 May; 19(5):605-14. PubMed ID: 20367532
[TBL] [Abstract][Full Text] [Related]
3. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.
Mayer EL; Krop IE
Clin Cancer Res; 2010 Jul; 16(14):3526-32. PubMed ID: 20634194
[TBL] [Abstract][Full Text] [Related]
4. Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss.
Hiscox S; Barrett-Lee P; Borley AC; Nicholson RI
Eur J Cancer; 2010 Aug; 46(12):2187-95. PubMed ID: 20471823
[TBL] [Abstract][Full Text] [Related]
5. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
7. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy.
Rucci N; Recchia I; Angelucci A; Alamanou M; Del Fattore A; Fortunati D; Susa M; Fabbro D; Bologna M; Teti A
J Pharmacol Exp Ther; 2006 Jul; 318(1):161-72. PubMed ID: 16627750
[TBL] [Abstract][Full Text] [Related]
9. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists.
Carducci MA; Jimeno A
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6296s-6300s. PubMed ID: 17062717
[TBL] [Abstract][Full Text] [Related]
10. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment.
Chung LW; Baseman A; Assikis V; Zhau HE
J Urol; 2005 Jan; 173(1):10-20. PubMed ID: 15592017
[TBL] [Abstract][Full Text] [Related]
11. Current trials using bone-targeting agents in prostate cancer.
Tu SM; Lin SH
Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
[TBL] [Abstract][Full Text] [Related]
12. Toward new horizons: the future of bisphosphonate therapy.
Lipton A
Oncologist; 2004; 9 Suppl 4():38-47. PubMed ID: 15459428
[TBL] [Abstract][Full Text] [Related]
13. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of aqueous extracts of Taraxacum officinale on growth and invasion of breast and prostate cancer cells.
Sigstedt SC; Hooten CJ; Callewaert MC; Jenkins AR; Romero AE; Pullin MJ; Kornienko A; Lowrey TK; Slambrouck SV; Steelant WF
Int J Oncol; 2008 May; 32(5):1085-90. PubMed ID: 18425335
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells.
Dorai T; Dutcher JP; Dempster DW; Wiernik PH
Prostate; 2004 Jun; 60(1):1-17. PubMed ID: 15129424
[TBL] [Abstract][Full Text] [Related]
16. Osteoprotegerin/osteoclastogenesis inhibitory factor decreases human prostate cancer burden in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice.
Yonou H; Kanomata N; Goya M; Kamijo T; Yokose T; Hasebe T; Nagai K; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2003 May; 63(9):2096-102. PubMed ID: 12727825
[TBL] [Abstract][Full Text] [Related]
17. Modulation of bone microenvironment with zoledronate enhances the therapeutic effects of STI571 and paclitaxel against experimental bone metastasis of human prostate cancer.
Kim SJ; Uehara H; Yazici S; He J; Langley RR; Mathew P; Fan D; Fidler IJ
Cancer Res; 2005 May; 65(9):3707-15. PubMed ID: 15867366
[TBL] [Abstract][Full Text] [Related]
18. Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment.
Pohorelic B; Singh R; Parkin S; Koro K; Yang AD; Egan C; Magliocco A
Breast Cancer Res Treat; 2012 May; 133(1):201-14. PubMed ID: 21894461
[TBL] [Abstract][Full Text] [Related]
19. Mechanisms of tumor metastasis to the bone: challenges and opportunities.
Reddi AH; Roodman D; Freeman C; Mohla S
J Bone Miner Res; 2003 Feb; 18(2):190-4. PubMed ID: 12568395
[TBL] [Abstract][Full Text] [Related]
20. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
